Key Highlights

• The FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia (AIHA).

• This is the second FDA Orphan Drug Designation for sovleplenib, following its October 2026 designation for primary immune thrombocytopenia (ITP).

• Orphan Drug Designation provides eligibility for 7 years of U.S. market exclusivity upon approval, along with tax credits and fee waivers.

• New Drug Applications for sovleplenib in primary ITP and warm AIHA are currently under regulatory review in China.

HUTCHMED (China) Limited(NASDAQ:HCM), a commercial-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia (AIHA). The designation, announced on November 4, 2026, marks the second orphan drug status for the company's selective spleen tyrosine kinase (Syk) inhibitor.

Understanding the Orphan Drug Designation

The FDA's Orphan Drug Designation program provides status to drugs and Biologics intended for the treatment, diagnosis, or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. The designation for sovleplenib in AIHA follows the compound's first Orphan Drug Designation for primary immune thrombocytopenia (ITP), which was announced in October 2026.

If sovleplenib receives FDA approval for AIHA, the Orphan Drug Designation would provide 7 years of U.S. market exclusivity. Additional benefits include tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act, and specialized regulatory guidance from the FDA during clinical development. These incentives are designed to encourage development of treatments for rare diseases that might otherwise lack sufficient commercial incentive.

About Autoimmune Hemolytic Anemia

AIHA is an autoimmune disorder characterized by the destruction of red blood cells due to the production of antibodies against red blood cell antigens. The incidence of AIHA is estimated at 0.8 to 3.0 per 100,000 adults per year, with an estimated prevalence of 17 per 100,000 adults and a death rate of 8 to 11 percent.

Warm AIHA (wAIHA) is the most common form of the condition, accounting for approximately 75 to 80 percent of all adult AIHA cases. The condition can lead to significant morbidity, including fatigue, shortness of breath, and cardiovascular complications related to chronic anemia.

Sovleplenib's Clinical Development Progress

Sovleplenib is a novel, selective inhibitor of Syk designed for once-daily oral administration. Syk plays a significant role in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.

In China, New Drug Applications for sovleplenib in primary ITP and wAIHA are currently under regulatory review by the National Medical Products Administration (NMPA). These filings are supported by data from the pivotal ESLIM-01 trial in primary ITP and the ESLIM-02 trial in wAIHA conducted in China.

HUTCHMED retains all worldwide rights to sovleplenib, which gives the company full control over the drug's commercial strategy and pricing across global markets.

Company Background and Pipeline Context

HUTCHMED is a Hong Kong-based biopharmaceutical company listed on Nasdaq, AIM, and the Hong Kong Stock Exchange. The company focuses on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Since its inception, HUTCHMED has brought four medicines to market in China, with the first also approved globally including in the U.S., Europe, and Japan.

The dual Orphan Drug Designations for sovleplenib position the compound as a potential treatment across multiple rare autoimmune conditions, broadening its commercial opportunity beyond oncology where HUTCHMED has historically concentrated its pipeline.

The Broader Perspective

The second Orphan Drug Designation for sovleplenib within a matter of weeks underscores the FDA's recognition of unmet medical need in rare autoimmune blood disorders. For HUTCHMED, the designations provide both regulatory and commercial advantages as the company advances sovleplenib toward potential U.S. regulatory filings. The progression of the NDA reviews in China for both ITP and wAIHA indications could provide early commercial data that informs the company's global strategy for the drug.